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Abstract  
 
Multidrug resistance (MDR) is a kind of acquired resistance of microorganisms and cancer cells to 
chemotherapic drugs that are characterized by different chemical structure and different mechanism 
of action. Classic MDR is the consequence of the over-expression of a variety of proteins that 
extrude the chemotherapic from the cell, lowering its concentration below the effective one. The 
ABC (ATP Binding Cassette) is a ubiquitous and important family of such transporter proteins. 
Members of this super family are present in mammals as well as in prokaryotic organisms and use 
ATP as the energy source to activate the extrusion process. P-glycoprotein (Pgp) and Multidrug 
Resistance Proteins (MRP1 and sister proteins) are the most important and widely studied members 
of ABC super family. 
Our knowledge about the structures and functions of transporter proteins has definitely improved in 
recent years, following the resolution of the structure of bacterial pumps which opened the way to 
the building of homology models for the more complex Pgp and MRP. It can be anticipated that 
these results will have a strong impact on the design of more potent and safer MDR reverters. 
A huge number of small molecules, many of natural origin, are able to reverse multidrug resistance 
by inhibiting the functions of Pgp, MRP1 and sister proteins and their action has been considered a 
possible way to reverse MDR. However, while a few compounds have reached clinical trials, none 
of them has, so far, been cleared for therapeutic use. Two main reasons are at the base of this 
difficulty: i) MDR is a complex phenomenon that may arise from several different biochemical 
mechanisms, with the consequence that inhibition of transporter proteins may be insufficient to 
reverse it; ii) the physiological role of Pgp and sister proteins requires more potent modulators with 
proper selectivity and pharmacokinetic in order to avoid unwanted side effects. 
This paper first reviews the most recent discoveries on the structures and functions of the ABC 
super family, in particular Pgp and MRP. Then, the medicinal chemistry of MDR reverters, in light 
of these findings, is discussed and the molecules that are presently in development are reviewed. 
